评估心血管疾病中的脆弱性特异性治疗效果:系统性审查
Lily Zhong1,2, Saran Thanapluetiwong3,4, Kailin Xu4
1University of Connecticut School of Medicine, Farmington, CT, USA. zhong@uchc.edu.
Drugs & aging
|November 25, 2024
概括
心血管干预可能会以不同的方式使脆弱的老年人受益. 脆弱性评估可以帮助个性化治疗,以改善老年人群中心血管疾病 (CVD) 事件的结果.
科学领域:
- 老年学是一门学科.
- 心脏病学 心脏病学
- 临床试验 临床试验
背景情况:
- 临床医生会考虑对老年人进行个性化治疗的脆弱性评估.
- 关于心血管疾病 (CVD) 干预措施对脆弱与非脆弱的老年人的差异性益处存在不确定性.
研究的目的:
- 系统地审查关于心血管疾病干预措施是否为脆弱和非脆弱的老年人提供类似的好处的证据.
- 评估脆弱性评估在优化心血管疾病干预方面的潜在实用性.
主要方法:
- 在PubMed和Embase的系统文献搜索 (2007年1月至2024年9月),遵循PRISMA指南.
- 包括随机对照试验与心血管疾病结局和脆弱性特定的治疗效果数据.
- 提取有关人口特征,干预,随访,脆弱性测量,结果和子组效应的数据;结果由于异质性而未聚合.
主要成果:
- 从151项已识别的研究中,包括了18项研究 (12项偏差风险较低).
- 干预的有效性各不相同:在弱体中更有效 (2项研究),在弱体中更不有效 (3项研究),同样有效 (7项研究),不确定的 (6项研究).
- 一些治疗方法显示出类似的危险比率,但在脆弱患者中绝对风险降低更大.
结论:
- 心血管干预可能根据患者的脆弱性提供不同的好处.
- 研究结果支持脆弱性评估对优化老年人心血管治疗策略的有用性.
相关概念视频
01:23Assessment of the Cardiovascular System I: Subjective Data
278
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
278
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
01:22Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316